Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 7, 2026, 11:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 338 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Treatment of pyrexia Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Post-Operative Treatment With Ketorolac After Abdominal Myomectomy

NCT00845754
View directory record Official record
Conditions
Febrile Morbidity, Pain
Interventions
ketorolac, saline
Drug
Lead sponsor
Ascher-Walsh, Charles, M.D.
Individual
Eligibility
18 Years and older · Female only
Enrollment
112 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2001
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 17, 2009 · Synced Sep 7, 2026, 11:02 AM EDT
Completed Phase 3 Interventional Results available

Study of Efficacy and Safety of Canakinumab in Patients With Hereditary Periodic Fevers

NCT02059291
View directory record Official record
Conditions
Hereditary Periodic Fevers
Interventions
Canakinumab, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
1 Month and older
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
3
States / cities
Los Angeles, California • Ann Arbor, Michigan • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 16, 2018 · Synced Sep 7, 2026, 11:02 AM EDT
Recruiting Phase 1 Interventional

KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer

NCT05483491
View directory record Official record
Conditions
Gastric Cancer, Breast Cancer, Cervical Cancer, Lung Cancer
Interventions
KK-LC-1 TCR-T cells, Aldesleukin
Biological · Drug
Lead sponsor
Christian Hinrichs
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
2
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Sep 7, 2026, 11:02 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Pharmacokinetics of UV-4B Solution Administered Orally as Multiple Ascending Doses to Healthy Subjects

NCT02696291
View directory record Official record
Conditions
Viral Infection
Interventions
UV-4B 30 mg oral solution, UV-4B 75 mg oral solution, UV-4B 150 mg oral solution, UV-4B X mg (dose to be determined) oral solution, UV-4B Y mg (dose to be determined) oral solution, Placebo
Drug
Lead sponsor
Emergent BioSolutions
Industry
Eligibility
18 Years to 45 Years
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
2
States / cities
Dallas, Texas • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 17, 2024 · Synced Sep 7, 2026, 11:02 AM EDT
Completed Phase 2 Interventional Results available

Gulf War Illness: Evaluation of an Innovative Detoxification Program

NCT01672710
View directory record Official record
Conditions
Gulf War Illness
Interventions
plain crystalline niacin, exercise, sauna
Drug
Lead sponsor
University at Albany
Other
Eligibility
Not listed
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Annapolis, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 12, 2020 · Synced Sep 7, 2026, 11:02 AM EDT
Not listed No phase listed Observational

Therapeutic Use of Contrast Ultrasound in Acute Coronary Artery Disease

NCT04732091
View directory record Official record
Conditions
Acute Myocardial Infarction, Unstable Angina
Interventions
Therapeutic ultrasound with 20 usec
Procedure
Lead sponsor
University of Sao Paulo General Hospital
Other
Eligibility
30 Years and older
Enrollment
540 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 9, 2023 · Synced Sep 7, 2026, 11:02 AM EDT
Not listed Phase 2 Interventional

Cisplatin, Metronomic Low-Dose Interferon Alfa, Gemcitabine, and Fever-Range Whole-Body Hyperthermia in Treating Patients With Inoperable or Metastatic Pancreatic Cancer

NCT00082862
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
recombinant interferon alfa, cisplatin, gemcitabine hydrochloride, hyperthermia treatment
Biological · Drug · Procedure
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 12, 2012 · Synced Sep 7, 2026, 11:02 AM EDT
Completed No phase listed Observational

Fatigue and Symptom Burden in Low-Risk Cancer Patients Undergoing Treatment for Febrile Neutropenia

NCT00503854
View directory record Official record
Conditions
Fatigue, Febrile Neutropenia, Solid Neoplasm
Interventions
Questionnaire
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 21, 2018 · Synced Sep 7, 2026, 11:02 AM EDT
Active, not recruiting No phase listed Observational

Self Reported Pain in Women While Undergoing Treatment for Non-metastatic Breast Cancer

NCT04174742
View directory record Official record
Conditions
Breast, Breast Cancer
Interventions
pegfilgrastim
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older · Female only
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2041
U.S. locations
2
States / cities
Charlotte, North Carolina • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Sep 7, 2026, 11:02 AM EDT
Withdrawn Phase 2 Interventional

Active Temperature Management After Cardiac Surgery and Its Effect on Postoperative Cognitive Dysfunction

NCT03947671
View directory record Official record
Conditions
Cardiac Surgery, Post-operative Cognitive Dysfunction, Fever
Interventions
Rapr Rounds Hyper/Hypothermia Wraps, Acetaminophen
Device · Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
20 Years to 89 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 31, 2024 · Synced Sep 7, 2026, 11:02 AM EDT
Recruiting Not applicable Interventional

GOLD: Brief Intervention to Reduce Anxiety and Promote Resilience in Families of Youth With Cancer

NCT05415007
View directory record Official record
Conditions
Cancer
Interventions
GOLD Program, Treatment as usual (TAU)
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
8 Years to 18 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 26, 2026 · Synced Sep 7, 2026, 11:02 AM EDT
Terminated Phase 2 Interventional Results available

Using MRI-Guided Laser Heat Ablation to Induce Disruption of the Peritumoral Blood Brain Barrier to Enhance Delivery and Efficacy of Treatment of Pediatric Brain Tumors

NCT02372409
View directory record Official record
Conditions
Glioma, Pilocytic Astrocytoma, Anaplastic Astrocytoma, Glioblastoma, Mixed Oligoastrocytoma, Mixed Glioma, Oligodendroglioma, Optic Glioma, Astrocytoma
Interventions
MRI-guided laser ablation, Doxorubicin, Etoposide, Dynamic contrast-enhanced (DCE) MRI, Dynamic susceptibility contrast (DSC) MRI
Device · Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
3 Years to 21 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 31, 2024 · Synced Sep 7, 2026, 11:02 AM EDT
Recruiting Phase 2 Interventional

Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer

NCT04107077
View directory record Official record
Conditions
Gastric Cancer, Peritoneal Carcinomatosis
Interventions
Cisplatin, Mitomycin
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Sep 7, 2026, 11:02 AM EDT
Completed Not applicable Interventional Results available

HypErthermia as an Additional Treatment for the Biology and Experience of Depression

NCT05041361
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Cognitive Behavioral Therapy (CBT), Whole-Body Hyperthermia (WBH)
Behavioral · Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Sep 7, 2026, 11:02 AM EDT
Completed Phase 3 Interventional

Treatment of Neutropenic Patients With Fever Who Are Suspected to Have A Gram Positive Infection

NCT00035425
View directory record Official record
Conditions
Febrile Neutropenia
Interventions
linezolid, vancomycin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
13 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
16
States / cities
Los Angeles, California • Springfield, Illinois • The Bronx, New York + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2009 · Synced Sep 7, 2026, 11:02 AM EDT
Terminated Phase 4 Interventional

The Timing of Prophylactic Antibiotics in Cesarean Section and the Risk of Post-operative Febrile Morbidity

NCT00133029
View directory record Official record
Conditions
Cesarean Section
Interventions
Timing of prophylactic antibiotic administration
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
Female only
Timeline
2004 – 2006
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 14, 2016 · Synced Sep 7, 2026, 11:02 AM EDT
Completed Phase 1 Interventional

Administration of TAA-Specific CTLs; Hodgkin or Non-Hodgkin Lymphoma; TACTAL

NCT01333046
View directory record Official record
Conditions
Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Hodgkin Disease
Interventions
Antigen-Escalation Stage, Dose-Escalation Stage, azacytidine and multiTAA T cells Stage, Pediatric multiTAA T cells Stage
Biological
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2026
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 7, 2026, 11:02 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Chronic Heat Therapy for Improving Vascular Health

NCT02518399
View directory record Official record
Conditions
Cardiovascular Diseases
Interventions
Heat therapy, Thermoneutral water immersion
Other
Lead sponsor
University of Oregon
Other
Eligibility
18 Years to 40 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Eugene, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 25, 2017 · Synced Sep 7, 2026, 11:02 AM EDT
Completed Phase 3 Interventional

Safety and Effectiveness of Ciclesonide Nasal Spray in Children (6 to 11 Years) With Perennial Allergic Rhinitis (BY9010/M1-403)

NCT00163514
View directory record Official record
Conditions
Perennial Allergic Rhinitis, Allergic Rhinitis, Hay Fever
Interventions
Ciclesonide
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
6 Years to 11 Years
Enrollment
636 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
58
States / cities
Oxford, Alabama • Huntington Beach, California • Mission Viejo, California + 52 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2016 · Synced Sep 7, 2026, 11:02 AM EDT
Completed No phase listed Observational Results available

Caspofungin or Micafungin as Empiric Antifungal Therapy for Persistent Fever and Neutropenia

NCT00723073
View directory record Official record
Conditions
Febrile Neutropenia
Interventions
Not listed
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
323 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 30, 2010 · Synced Sep 7, 2026, 11:02 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Intramuscular Heating Rates of a Chattanooga Intelect XT Therapeutic Ultrasound

NCT03816709
View directory record Official record
Conditions
Ultrasound Therapy; Complications
Interventions
Therapeutic Ultrasound
Device
Lead sponsor
North Dakota State University
Other
Eligibility
18 Years to 35 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated May 26, 2021 · Synced Sep 7, 2026, 11:02 AM EDT
Not listed Phase 2 Interventional

Whole Body Hyperthermia Combined With Chemotherapy in Treating Patients With Metastatic Breast, Ovarian, Endometrial, or Cervical Cancer

NCT00003135
View directory record Official record
Conditions
Breast Cancer, Cervical Cancer, Endometrial Cancer, Ovarian Cancer
Interventions
fluorouracil, pegylated liposomal doxorubicin hydrochloride, hyperthermia treatment
Drug · Procedure
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older · Female only
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 29, 2009 · Synced Sep 7, 2026, 11:02 AM EDT
Not yet recruiting Phase 2 Interventional

Laser Interstitial Thermal Therapy (LiTT) With Cemiplimab or Other Chemotherapy in Recurrent Glioblastomas

NCT07620548
View directory record Official record
Conditions
Glioblastoma, Glioblastoma, IDH-wildtype, Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype
Interventions
NeuroBlate® Laser Ablation Laser Interstitial Thermal Therapy, Cemiplimab, Chemotherapy
Device · Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
2
States / cities
Rochester, Minnesota • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Sep 7, 2026, 11:02 AM EDT
Completed Phase 3 Interventional

Safety and Efficacy of Ciclesonide in Pediatric Patients (6 to 11 Years of Age) With Seasonal Allergic Rhinitis (BY9010/M1-417)

NCT00305487
View directory record Official record
Conditions
Hay Fever, Seasonal Allergic Rhinitis
Interventions
Ciclesonide nasal spray
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
6 Years to 11 Years
Enrollment
660 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
71
States / cities
Birmingham, Alabama • Hot Springs, Arkansas • Costa Mesa, California + 65 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2016 · Synced Sep 7, 2026, 11:02 AM EDT